About Us /
"We believe the PolyRemedy solution has the potential to truly revolutionize the wound care market."
— Tom Rodgers, Advanced Technology Ventures
President and Chief Operating Officer
Altegra Health
Miami Lakes, FL
With more than 25 years of start-up, deal-making and operating experience in healthcare services and life sciences, Kevin joined Altegra Health, formerly Social Services Coordinators, in April 2009 to oversee the organizations day-to-day operations. Altegra Health is the leading provider of eligibility-based revenue-cycle management services to health plans nationwide. As President and Chief Executive Officer, Kevin’s responsibilities include Outreach and Operations, Information Technology, Product Development, Sales and Account Management, Government Relations, Finance and Project Management.
Prior to joining Altegra Health, Kevin was an executive-in-residence with Bain Capital Ventures and SV Life Sciences. He previously served as Executive Vice President and Chief Development Officer of PolyMedica Corporation, Senior Vice President of BG Medicine, and Chief Operating Officer of the Synergy Informatics division of Quintiles Transnational.
Kevin holds a BA in Psychology from Columbia University and an MBA from Harvard Business School.
President and CEO
PolyRemedy, Inc.
Mountain View, CA
A life sciences executive with a successful track record driving growth by building patient-focused companies, Mark joined PolyRemedy in January 2010. He was previously President and CEO of HyperMed, Inc., a commercial stage start-up medical device company dedicated to improving the diagnosis and associated outcomes of advanced vascular interventions using novel hyperspectrial imaging technology. Most relevant to PolyRemedy, Mark was President USA of Kinetic Concepts Inc. (NYSE: KCI), a leading global medical technology company in advanced wound care whose breakthrough technology has enabled clinicians to improve the lives of over 1 million patients. At KCI, he reinvigorated the business by growing revenues from $650 million to $950 million and expanding company profits by 62 percent over 20 months.
As VP Corporate Development for OraPharma, Inc., a drug-device combination therapy to treat periodontal disease, he co-led a successful IPO and eventual sale to Johnson & Johnson. Mark also served in various sales, marketing and manufacturing roles with Eli Lilly and Company and was a member of The Boston Consulting Group for six years.
Mark holds a MBA from the Wharton School at the University of Pennsylvania and a BS in Industrial Engineering from Penn State University.
Managing Partner
Flybridge Capital Partners
Boston, MA
Michael is a General Partner at Flybridge Capital Partners, focused on information technology, healthcare and medical technology investments with a particular focus on opportunities involving the convergence of healthcare and IT and technology-enabled business services.
Prior to Flybridge, Michael served in senior positions at Polaris Venture Partners, GCC Investments, Wasserstein Perella & Co., Morgan Stanley & Co. and Credit Suisse First Boston.
Michael currently serves on the board of the National Venture Capital Association, as Chair of the Entrepreneurship Committee of the Massachusetts Information Collaborative, and as co-Founder of the 12 x 12 program. He also serves on the investment committee of the Parners Innovation Healthcare Fund, is a member of the Executive Business Advisory Council for Mass General Hospital for Children, and a trustee and investment committee member for the Massachusetts Eye and Ear Infirmary.
Michael received a BA with honors in Chemistry from Williams College and an MBA from Harvard Business School.
Partner
MedVenture Associates
Emeryville, CA
Charles Liamos joined MedVenture Associates in September 2006 as Executive in Residence and became a Partner in January 2007. He brings more than 10 years of experience in finance and operations leadership positions and more than 11 years in the diabetes market, where he had leadership roles in developing technologies and growing businesses.
Prior to joining MVA, Charlie was President and CEO of Fovioptics, Inc., a medical device company focused on blood glucose monitoring. He previously served as Chief Operating Officer and Chief Financial Officer of TheraSense, Inc.
Charlie holds a BS in Finance from University of Vermont, Burlington, and is a graduate of GEs Financial Management Program. In addition to serving on the PolyRemedy board, he currently sits on the boards Insulet Corp., OptiScan Biomedical, Sonoma Orthopedic Products, Inc., SoundID, Inc., Southern Implants, Inc., and Vital Therapies, Inc.
General Partner
Delphi Ventures
Menlo Park, CA
Doug is a General Partner at Delphi Ventures, focused on medical devices and diagnostics. Prior to Delphi, Doug served as an Associate with Alex. Brown's Healthcare Investment Banking Group in San Francisco. While at Alex. Brown, Doug assisted in the execution of over dozen financing and merger transactions involving both Fortune 500 and venture backed medical technology companies.
In addition to serving on the PolyRemedy board, Doug currently sits on the board of the following companies: Anulex Technologies Inc., Ivantis, Inc., Tandem Diabetes, Care, Inc., TriVascular, Inc., and Vibrynt, Inc.
Doug holds an AB from Dartmouth College located in Hanover, New Hampshire.
Partner
Advanced Technology Ventures
Palo Alto, CA
Tom joined ATV in 2004, and focuses on healthcare investments with a specific focus on medical devices, diagnostics, payer solutions and technology enabled services. In addition to his role on the PolyRemedy board, he also represents ATV on the boards of Aperio, Gynesonics, and Valeritas. He is also an observer on the boards of ConcepTx and Zeltiq Aesthetics.
Prior to joining ATV, Tom had 12 years of operating experience in the healthcare industry. Most recently, he was Vice President of corporate strategy and business development at McKesson Corporation, where he managed a number of acquisitions and strategic initiatives, including launching McKessons Medicare Prescription Drug Card, e-prescribing strategies, and the development of the companys generics program.
Prior to McKesson, Tom was a Product Manager at Genentech and was responsible for the successful Nutropin, Nutropin AQ and Pulmozyme franchises. In addition, he managed sales and oversaw healthcare strategy for FitLinxx, a venture-backed startup that pioneered the fitness and rehab monitoring market. His management background also includes five years consulting at The Wilkerson Group, where he focused on medical devices and diagnostics.
Mr. Rodgers holds an MBA from the Wharton School and a BA from the University of Pennsylvania and was an All American rugby player. He also admits he was once the New Hampshire State high school math champion.